Exploring RPSA as a biomarker for pancreatic cancer prognosis
RPSA as a Potential Prognostic Biomarker of PDAC
NA · CHU de Reims · NCT04575363
This study is testing if a protein found in blood can help predict how pancreatic cancer will progress in patients who have had surgery or chemotherapy.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CHU de Reims (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Reims) |
| Trial ID | NCT04575363 on ClinicalTrials.gov |
What this trial studies
This study investigates the role of ribosomal protein SA (RPSA) as a potential prognostic biomarker for pancreatic ductal adenocarcinoma (PDAC). It aims to analyze blood samples from patients treated at Reims University Hospital for resectable or potentially resectable pancreatic tumors, with or without prior chemotherapy. The study seeks to determine if RPSA expression correlates with tumor invasion and metastatic potential, addressing the current lack of effective biomarkers for PDAC prognosis.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old with a diagnosis of resectable or potentially resectable pancreatic tumors being treated at Reims University Hospital.
Not a fit: Patients with a prior history of cancer or those diagnosed with conditions other than PDAC may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic assessments for patients with pancreatic cancer, enabling more personalized treatment strategies.
How similar studies have performed: While the exploration of RPSA as a biomarker is relatively novel, similar studies have shown promise in identifying biomarkers for other cancers, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
inclusion criteria : * Patients treated at the Reims University Hospital for a resectable or potentially resectable pancreatic tumor, with or without neoadjuvant chemotherapy * Adults (aged more than 18 years old) * Patients who have signed the informed consent form exclusion criteria : * Patients with a prior history of cancer (excluding basal cell carcinoma or in situ cervical cancer that received conventional cancer treatment). * Minors * Patients for whom PDAC is not the retained diagnosis
Where this trial is running
Reims
- Damien JOLLY — Reims, France (RECRUITING)
Study contacts
- Study coordinator: Jean-Baptiste OUDART
- Email: joudart@chu-reims.fr
- Phone: 03 10 73 62 87
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pancreatic Ductal Adenocarcinoma, Pancreatic ductal adenocarcinoma, Ribosomal protein SA, prognosis biomarker